Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Nirav N. Shah MD

Associate Professor

Institution: Medical College of Wisconsin
Department: Medicine
Division: Hematology and Oncology - Medicine
Program: Bone Marrow Transplant

Member of the Cancer Center
Member of the Center for Immunology


Publications (69)

  • Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report. (Zhou Z, Nath R, Cerny J, Wang HL, Zhang MJ, Abdel-Azim H, Agrawal V, Ahmed G, Al-Homsi AS, Aljurf M, Alkhateeb HB, Assal A, Bacher U, Bajel A, Bashir Q, Battiwalla M, Bhatt VR, Byrne M, Cahn JY, Cairo M, Choe H, Copelan E, Cutler C, Damlaj MB, DeFilipp Z, De Lima M, Diaz MA, Farhadfar N, Foran J, Freytes CO, Gerds AT, Gergis U, Grunwald MR, Gul Z, Hamadani M, Hashmi S, Hertzberg M, Hildebrandt GC, Hossain N, Inamoto Y, Isola L, Jain T, Kamble RT, Khan MW, Kharfan-Dabaja MA, Kebriaei P, Kekre N, Khera N, Lazarus HM, Liesveld JL, Litzow M, Liu H, Marks DI, Martino R, Mathews V, Mishra A, Murthy HS, Nagler A, Nakamura R, Nathan S, Nishihori T, Olin R, Olsson RF, Palmisiano N, Patel SS, Patnaik MM, Pawarode A, Perales MA, Politikos I, Popat U, Rizzieri D, Sandmaier BM, Savani BN, Seo S, Shah NN, Uy GL, Valcárcel D, Verdonck LF, Waller EK, Wang Y, Weisdorf D, Wirk B, Wong E, Yared JA, Saber W) Blood Adv 2020 Jul 14;4(13):3180-3190 PMID: 32663298 PMCID: PMC7362362 SCOPUS ID: 2-s2.0-85088320644 07/15/2020    
  • Ixazomib for Chronic Graft-versus-Host Disease Prophylaxis following Allogeneic Hematopoietic Cell Transplantation. (Chhabra S, Visotcky A, Pasquini MC, Zhu F, Tang X, Zhang MJ, Thompson R, Abedin S, D'Souza A, Dhakal B, Drobyski WR, Fenske TS, Jerkins JH, Douglas Rizzo J, Runaas L, Saber W, Shah NN, Shaw BE, Horowitz MM, Hari PN, Hamadani M) Biol Blood Marrow Transplant 2020 Jul 09 PMID: 32653622 SCOPUS ID: 2-s2.0-85089134303 07/13/2020    
  • Treatment-Emergent Tumor Lysis Syndrome With PI3Kδ-γ Inhibition After CAR T-Cell Therapy for Chronic Lymphocytic Leukemia. (Shah NN, Jerkins JH, Johnson BD, Hari P) JCO Oncol Pract 2020 Sep;16(9):613-614 PMID: 32603254 SCOPUS ID: 2-s2.0-85090870606 07/01/2020    
  • Severity of Cytokine Release Syndrome and Its Association with Infections after T Cell-Replete Haploidentical Related Donor Transplantation. (Abid MB, Hamadani M, Szabo A, Hari PN, Graham MB, Frank MO, Collier WS, Abedin S, Jerkins JH, Pasquini MC, Runaas L, Shah NN, Chhabra S) Biol Blood Marrow Transplant 2020 Sep;26(9):1670-1678 PMID: 32562858 SCOPUS ID: 2-s2.0-85087739042 06/21/2020    
  • Intrathecal chemotherapy for management of steroid-refractory CAR T-cell-associated neurotoxicity syndrome. (Shah NN, Johnson BD, Fenske TS, Raj RV, Hari P) Blood Adv 2020 May 26;4(10):2119-2122 PMID: 32407473 PMCID: PMC7252557 SCOPUS ID: 2-s2.0-85086848668 05/15/2020    
  • Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial. (Jagasia M, Perales MA, Schroeder MA, Ali H, Shah NN, Chen YB, Fazal S, Dawkins FW, Arbushites MC, Tian C, Connelly-Smith L, Howell MD, Khoury HJ) Blood 2020 May 14;135(20):1739-1749 PMID: 32160294 PMCID: PMC7229262 SCOPUS ID: 2-s2.0-85083637011 03/12/2020       17 Citations
  • Propranolol inhibits molecular risk markers in HCT recipients: a phase 2 randomized controlled biomarker trial. (Knight JM, Rizzo JD, Hari P, Pasquini MC, Giles KE, D'Souza A, Logan BR, Hamadani M, Chhabra S, Dhakal B, Shah N, Sriram D, Horowitz MM, Cole SW) Blood Adv 2020 02 11;4(3):467-476 PMID: 32027744 PMCID: PMC7013267 SCOPUS ID: 2-s2.0-85082178004 02/07/2020       3 Citations
  • Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia. (Badar T, Shah NN) Curr Treat Options Oncol 2020 02 05;21(2):16 PMID: 32025828 SCOPUS ID: 2-s2.0-85079049524 02/07/2020       3 Citations
  • Fludarabine/Busulfan Conditioning-Based Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis: Role of Ruxolitinib in Improving Survival Outcomes. (Chhabra S, Narra RK, Wu R, Szabo A, George G, Michaelis LC, D'Souza A, Dhakal B, Drobyski WR, Fenske TS, Jerkins JH, Pasquini MC, Rizzo RD, Saber W, Shah NN, Shaw BE, Hamadani M, Hari PN) Biol Blood Marrow Transplant 2020 May;26(5):893-901 PMID: 31982543 SCOPUS ID: 2-s2.0-85080146585 01/27/2020       3 Citations
  • Trends in postrelapse survival in classic Hodgkin lymphoma patients after experiencing therapy failure following auto-HCT. (Badar T, Epperla N, Szabo A, Borson S, Vaughn J, George G, Saini N, Shah AR, Patel RD, Ahmed S, Shah NN, Cashen AF, Hamadani M, Fenske TS) Blood Adv 2020 01 14;4(1):47-54 PMID: 31899797 PMCID: PMC6960457 SCOPUS ID: 2-s2.0-85078133666 01/04/2020       3 Citations
  • Gut microbiome and CAR-T therapy. (Abid MB, Shah NN, Maatman TC, Hari PN) Exp Hematol Oncol 2019;8:31 PMID: 31827982 PMCID: PMC6862813 12/13/2019    
  • Vedolizumab for prevention of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. (Chen YB, Shah NN, Renteria AS, Cutler C, Jansson J, Akbari M, Chen C, Quadri S, Parfionovas A, Devine SM) Blood Adv 2019 12 10;3(23):4136-4146 PMID: 31821456 PMCID: PMC6963235 SCOPUS ID: 2-s2.0-85083376318 12/11/2019       4 Citations
  • Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia. (Frey NV, Shaw PA, Hexner EO, Pequignot E, Gill S, Luger SM, Mangan JK, Loren AW, Perl AE, Maude SL, Grupp SA, Shah NN, Gilmore J, Lacey SF, Melenhorst JJ, Levine BL, June CH, Porter DL) J Clin Oncol 2020 02 10;38(5):415-422 PMID: 31815579 SCOPUS ID: 2-s2.0-85079075868 12/10/2019       12 Citations
  • Allogeneic transplantation in elderly patients ≥65 years with non-Hodgkin lymphoma: a time-trend analysis. (Shah NN, Ahn KW, Litovich C, Sureda A, Kharfan-Dabaja MA, Awan FT, Ganguly S, Gergis U, Inwards D, Karmali R, Lazaryan A, Lekakis L, Munshi P, Nathan S, Saad AA, Solh M, Steinberg A, Vij R, Wood WA, Fenske TS, Smith S, Hamadani M) Blood Cancer J 2019 12 03;9(12):97 PMID: 31796726 PMCID: PMC6890709 SCOPUS ID: 2-s2.0-85075936084 12/05/2019       1 Citation
  • Lifitegrast ophthalmic solution for treatment of ocular chronic graft-versus-host disease. (Chhabra S, Jerkins JH, Conto JE, Zellner K, Shah NN, Hari PN, Hamadani M) Leuk Lymphoma 2020 04;61(4):869-874 PMID: 31762357 SCOPUS ID: 2-s2.0-85075533403 11/26/2019       2 Citations
  • Gut microbiome and CAR-T therapy (Abid MB, Shah NN, Maatman TC, Hari PN) Experimental Hematology and Oncology 19 November 2019;8(1) SCOPUS ID: 2-s2.0-85075584597 11/19/2019    
  • Myeloablative vs reduced intensity T-cell-replete haploidentical transplantation for hematologic malignancy. (Solomon SR, St Martin A, Shah NN, Fatobene G, Al Malki MM, Ballen KK, Bashey A, Bejanyan N, Bolaños Meade J, Brunstein CG, DeFilipp Z, Champlin RE, Fuchs EJ, Hamadani M, Hematti P, Kanakry CG, McGuirk JP, McNiece IK, Ciurea SO, Pasquini MC, Rocha V, Romee R, Patel SS, Vasu S, Waller EK, Wingard JR, Zhang MJ, Eapen M) Blood Adv 2019 10 08;3(19):2836-2844 PMID: 31582392 PMCID: PMC6784523 SCOPUS ID: 2-s2.0-85073446898 10/05/2019       6 Citations
  • Contemporary Outcomes for Advanced-Stage Classical Hodgkin Lymphoma in the U.S.: Analysis of Surveillance, Epidemiology, and End Results Database. (Guru Murthy GS, Szabo A, Hamadani M, Fenske TS, Shah NN) Oncologist 2019 11;24(11):1488-1495 PMID: 31467178 PMCID: PMC6853108 SCOPUS ID: 2-s2.0-85071466837 08/31/2019    
  • Phase I/II trial of bendamustine, ixazomib, and dexamethasone in relapsed/refractory multiple myeloma. (Dhakal B, D'Souza A, Hamadani M, Arce-Lara C, Schroeder K, Chhabra S, Shah NN, Gauger K, Keaton T, Pasquini M, Hari P) Blood Cancer J 2019 07 29;9(8):56 PMID: 31358733 PMCID: PMC6663939 SCOPUS ID: 2-s2.0-85069933026 07/31/2019       2 Citations
  • Incidence and characteristics of engraftment syndrome after autologous hematopoietic cell transplantation in light chain amyloidosis. (Badar T, Khan MA, Szabo A, Drobyski W, Chhabra S, Dhakal B, Fenske TS, Hamadani M, Hari P, Jerkins JH, Shah NN, Shaw BE, D'Souza A) Amyloid 2019 Dec;26(4):210-215 PMID: 31347424 SCOPUS ID: 2-s2.0-85074118154 07/28/2019    
  • Factors Associated With Unplanned 30-Day Readmissions After Hematopoietic Cell Transplantation Among US Hospitals. (Dhakal B, Giri S, Levin A, Rein L, Fenske TS, Chhabra S, Shah NN, Szabo A, D'Souza A, Pasquini M, Hari P, Hamadani M) JAMA Netw Open 2019 07 03;2(7):e196476 PMID: 31276175 SCOPUS ID: 2-s2.0-85068511187 07/06/2019       2 Citations
  • Postrelapse survival in diffuse large B-cell lymphoma after therapy failure following autologous transplantation. (Epperla N, Badar T, Szabo A, Vaughn J, Borson S, Saini NY, Patel RD, Shah NN, Hamadani M, Ahmed S, Cashen AF, Fenske TS) Blood Adv 2019 06 11;3(11):1661-1669 PMID: 31167818 PMCID: PMC6560348 SCOPUS ID: 2-s2.0-85067501987 06/07/2019       4 Citations
  • A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL. (Mato AR, Roeker LE, Eyre TA, Nabhan C, Lamanna N, Hill BT, Brander DM, Barr PM, Lansigan F, Cheson BD, Singavi AK, Yazdy MS, Shah NN, Allan JN, Bhavsar EB, Rhodes J, Kennard K, Schuster SJ, Williams AM, Skarbnik AP, Goy AH, Goodfriend JM, Dorsey C, Coombs CC, Tuncer H, Ujjani CS, Jacobs R, Winter AM, Pagel JM, Bailey N, Schuh A, Shadman M, Sitlinger A, Weissbrot H, Muralikrishnan S, Zelenetz A, Kirkwood AA, Fox CP) Blood Adv 2019 05 28;3(10):1568-1573 PMID: 31101647 PMCID: PMC6538868 SCOPUS ID: 2-s2.0-85067043385 05/19/2019       5 Citations
  • Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice. (Roeker LE, Fox CP, Eyre TA, Brander DM, Allan JN, Schuster SJ, Nabhan C, Hill BT, Shah NN, Lansigan F, Yazdy M, Cheson BD, Lamanna N, Singavi AK, Coombs CC, Barr PM, Skarbnik AP, Shadman M, Ujjani CS, Tuncer HH, Winter AM, Rhodes J, Dorsey C, Morse H, Kabel C, Pagel JM, Williams AM, Jacobs R, Goy A, Muralikrishnan S, Pearson L, Sitlinger A, Bailey N, Schuh A, Kirkwood AA, Mato AR) Clin Cancer Res 2019 07 15;25(14):4264-4270 PMID: 31004001 SCOPUS ID: 2-s2.0-85069054532 04/21/2019       11 Citations
  • Efficacy, Toxicity, and Infectious Complications in Ruxolitinib-Treated Patients with Corticosteroid-Refractory Graft-versus-Host Disease after Hematopoietic Cell Transplantation. (Abedin S, McKenna E, Chhabra S, Pasquini M, Shah NN, Jerkins J, Baim A, Runaas L, Longo W, Drobyski W, Hari PN, Hamadani M) Biol Blood Marrow Transplant 2019 08;25(8):1689-1694 PMID: 30965140 SCOPUS ID: 2-s2.0-85065022222 04/10/2019       17 Citations
  • A Phase 2 Study of Pembrolizumab during Lymphodepletion after Autologous Hematopoietic Cell Transplantation for Multiple Myeloma. (D'Souza A, Hari P, Pasquini M, Braun T, Johnson B, Lundy S, Couriel D, Hamadani M, Magenau J, Dhakal B, Shah NN, Riwes M, Parkin B, Reddy P, Pawarode A) Biol Blood Marrow Transplant 2019 08;25(8):1492-1497 PMID: 30959163 SCOPUS ID: 2-s2.0-85065451525 04/09/2019       5 Citations
  • Multi Targeted CAR-T Cell Therapies for B-Cell Malignancies. (Shah NN, Maatman T, Hari P, Johnson B) Front Oncol 2019;9:146 PMID: 30915277 PMCID: PMC6423158 SCOPUS ID: 2-s2.0-85063343499 03/28/2019    
  • Comparison of Graft Acquisition and Early Direct Charges of Haploidentical Related Donor Transplantation versus Umbilical Cord Blood Transplantation. (Kanate AS, Szabo A, Raj RV, Bower K, Grulke R, Shah N, Ross KG, Cumpston A, Craig M, Pasquini MC, Shah N, Hari P, Hamadani M, Chhabra S) Biol Blood Marrow Transplant 2019 07;25(7):1456-1464 PMID: 30878605 SCOPUS ID: 2-s2.0-85064323899 03/18/2019       6 Citations
  • Chimeric antigen receptor modified T cell therapy in B cell non-Hodgkin lymphomas. (Levin A, Shah NN) Am J Hematol 2019 05;94(S1):S18-S23 PMID: 30652353 SCOPUS ID: 2-s2.0-85060610905 01/18/2019       6 Citations
  • Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: a CIBMTR analysis. (Epperla N, Ahn KW, Litovich C, Ahmed S, Battiwalla M, Cohen JB, Dahi P, Farhadfar N, Farooq U, Freytes CO, Ghosh N, Haverkos B, Herrera A, Hertzberg M, Hildebrandt G, Inwards D, Kharfan-Dabaja MA, Khimani F, Lazarus H, Lazaryan A, Lekakis L, Murthy H, Nathan S, Nishihori T, Pawarode A, Prestidge T, Ramakrishnan P, Rezvani AR, Romee R, Shah NN, Sureda A, Fenske TS, Hamadani M) J Hematol Oncol 2019 01 10;12(1):6 PMID: 30630534 PMCID: PMC6329157 SCOPUS ID: 2-s2.0-85059829766 01/12/2019       9 Citations
  • Clinical Outcomes and Healthcare Resource Utilization for Gastrointestinal Acute Graft-versus-Host Disease after Allogeneic Transplantation for Hematologic Malignancy: A Retrospective US Administrative Claims Database Analysis. (Johnson BH, Taylor A, Kim G, Drahos J, Yang J, Akbari M, Shah NN) Biol Blood Marrow Transplant 2019 04;25(4):834-841 PMID: 30625389 SCOPUS ID: 2-s2.0-85061103905 01/10/2019       2 Citations
  • Allogenic transplant for non-hodgkin lymphoma (Narra RK, Shah NN) Hematopoietic Cell Transplantation for Malignant Conditions 1 January 2019:209-229 SCOPUS ID: 2-s2.0-85082261875 01/01/2019    
  • Multicenter Analysis of Advanced Stage Grade 3A Follicular Lymphoma Outcomes by Frontline Treatment Regimen. (Shah NN, Szabo A, Saba R, Strelec L, Kodali D, Vaughn JL, Esan O, Yang DT, Mato AR, Kanate AS, Olteanu H, Hamadani M, Fenske TS, Kenkre VP, Svoboda J, Cashen AF, Epperla N) Clin Lymphoma Myeloma Leuk 2019 02;19(2):95-102 PMID: 30581160 SCOPUS ID: 2-s2.0-85058679508 12/26/2018       2 Citations
  • Outcomes of Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation Performed in the Inpatient versus Outpatient Setting. (Guru Murthy GS, Hari PN, Szabo A, Pasquini M, Narra R, Khan M, Abedin S, Chhabra S, Dhakal B, D'Souza A, Drobyski WR, Rizzo JD, Runaas L, Shah NN, Shaw B, Saber W, Fenske T, Hamadani M) Biol Blood Marrow Transplant 2019 04;25(4):827-833 PMID: 30572109 SCOPUS ID: 2-s2.0-85059680507 12/21/2018       7 Citations
  • Outcomes and Toxicities of Programmed Death-1 (PD-1) Inhibitors in Hodgkin Lymphoma Patients in the United States: A Real-World, Multicenter Retrospective Analysis. (Bair SM, Strelec LE, Feldman TA, Ahmed G, Armand P, Shah NN, Singavi AN, Reddy N, Khan N, Andreadis C, Vu K, Huntington SF, Giri S, Ujjani C, Howlett C, Faheem M, Youngman MR, Nasta SD, Landsburg DJ, Schuster SJ, Svoboda J) Oncologist 2019 07;24(7):955-962 PMID: 30568021 PMCID: PMC6656463 SCOPUS ID: 2-s2.0-85058939991 12/21/2018       3 Citations
  • Safety and Effectiveness of Vedolizumab in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease: A Retrospective Record Review. (Fløisand Y, Lazarevic VL, Maertens J, Mattsson J, Shah NN, Zachée P, Taylor A, Akbari M, Quadri S, Parfionovas A, Chen YB) Biol Blood Marrow Transplant 2019 04;25(4):720-727 PMID: 30468919 SCOPUS ID: 2-s2.0-85059057830 11/24/2018       10 Citations
  • Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia. (Chhabra S, Ahn KW, Hu ZH, Jain S, Assal A, Cerny J, Copelan EA, Daly A, DeFilipp Z, Gadalla SM, Gale RP, Ganguly S, Hamilton BK, Hildebrandt GC, Hsu JW, Inamoto Y, Kanate AS, Khoury HJ, Lazarus HM, Litzow MR, Nathan S, Olsson RF, Pawarode A, Ringden O, Rowe JM, Saad A, Savani BN, Schouten HC, Seo S, Shah NN, Solh M, Stuart RK, Ustun C, Woolfrey AE, Yared JA, Alyea EP, Kalaycio ME, Popat U, Sobecks RM, Saber W) Blood Adv 2018 11 13;2(21):2922-2936 PMID: 30396912 PMCID: PMC6234373 SCOPUS ID: 2-s2.0-85064089410 11/07/2018       9 Citations
  • Early positron emission tomography/computed tomography as a predictor of response after CTL019 chimeric antigen receptor -T-cell therapy in B-cell non-Hodgkin lymphomas. (Shah NN, Nagle SJ, Torigian DA, Farwell MD, Hwang WT, Frey N, Nasta SD, Landsburg D, Mato A, June CH, Schuster SJ, Porter DL, Svoboda J) Cytotherapy 2018 12;20(12):1415-1418 PMID: 30385043 SCOPUS ID: 2-s2.0-85057563885 11/06/2018       8 Citations
  • Long-term outcomes of rituximab, temozolomide and high-dose methotrexate without consolidation therapy for lymphoma involving the CNS. (Nagle SJ, Shah NN, Ganetsky A, Landsburg DJ, Nasta SD, Mato A, Schuster SJ, Reshef R, Tsai DE, Svoboda J) Int J Hematol Oncol 2017 Dec;6(4):113-121 PMID: 30302232 PMCID: PMC6171986 10/12/2018    
  • Impact of Obesity on Clinical Outcomes of Elderly Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myeloid Malignancies. (Voshtina E, Szabo A, Hamadani M, Fenske TS, D'Souza A, Chhabra S, Saber W, Drobyski WR, Hari P, Shah NN) Biol Blood Marrow Transplant 2019 01;25(1):e33-e38 PMID: 30244105 SCOPUS ID: 2-s2.0-85055445894 09/24/2018    
  • Outcomes of Haploidentical Transplantation in Patients with Relapsed Multiple Myeloma: An EBMT/CIBMTR Report. (Sahebi F, Garderet L, Kanate AS, Eikema DJ, Knelange NS, Alvelo OFD, Koc Y, Blaise D, Bashir Q, Moraleda JM, Dreger P, Sanchez JF, Ciurea S, Schouten H, Shah NN, Verbeek M, Rösler W, Diez-Martin JL, Schoenland S, D'Souza A, Kröger N, Hari P) Biol Blood Marrow Transplant 2019 02;25(2):335-342 PMID: 30243581 PMCID: PMC6339830 SCOPUS ID: 2-s2.0-85055703569 09/24/2018       2 Citations
  • Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial. (Mato AR, Roeker LE, Allan JN, Pagel JM, Brander DM, Hill BT, Cheson BD, Furman RR, Lamanna N, Tam CS, Handunnetti S, Jacobs R, Lansigan F, Bhavsar E, Barr PM, Shadman M, Skarbnik AP, Goy A, Beach DF, Svoboda J, Pu JJ, Sehgal AR, Zent CS, Tuncer HH, Schuster SJ, Pickens PV, Shah NN, Rhodes J, Ujjani CS, Nabhan C) Am J Hematol 2018 11;93(11):1394-1401 PMID: 30132965 SCOPUS ID: 2-s2.0-85053839727 08/23/2018       20 Citations
  • Daratumumab in Primary Effusion Lymphoma. (Shah NN, Singavi AK, Harrington A) N Engl J Med 2018 08 16;379(7):689-690 PMID: 30110586 SCOPUS ID: 2-s2.0-85051817119 08/16/2018       10 Citations
  • Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States. (Mato AR, Thompson M, Allan JN, Brander DM, Pagel JM, Ujjani CS, Hill BT, Lamanna N, Lansigan F, Jacobs R, Shadman M, Skarbnik AP, Pu JJ, Barr PM, Sehgal AR, Cheson BD, Zent CS, Tuncer HH, Schuster SJ, Pickens PV, Shah NN, Goy A, Winter AM, Garcia C, Kennard K, Isaac K, Dorsey C, Gashonia LM, Singavi AK, Roeker LE, Zelenetz A, Williams A, Howlett C, Weissbrot H, Ali N, Khajavian S, Sitlinger A, Tranchito E, Rhodes J, Felsenfeld J, Bailey N, Patel B, Burns TF, Yacur M, Malhotra M, Svoboda J, Furman RR, Nabhan C) Haematologica 2018 09;103(9):1511-1517 PMID: 29880613 PMCID: PMC6119152 SCOPUS ID: 2-s2.0-85052872031 06/09/2018       40 Citations
  • Repurposing existing medications as cancer therapy: design and feasibility of a randomized pilot investigating propranolol administration in patients receiving hematopoietic cell transplantation. (Knight JM, Kerswill SA, Hari P, Cole SW, Logan BR, D'Souza A, Shah NN, Horowitz MM, Stolley MR, Sloan EK, Giles KE, Costanzo ES, Hamadani M, Chhabra S, Dhakal B, Rizzo JD) BMC Cancer 2018 May 24;18(1):593 PMID: 29793446 PMCID: PMC5968588 SCOPUS ID: 2-s2.0-85047544800 05/26/2018       10 Citations
  • Pharmacokinetics of High-Dose Propylene Glycol-Free Melphalan in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation. (Dhakal B, D'Souza A, Lakshman A, Hamadani M, Chhabra S, Thompson R, Shah N, Pasquini M, Hari P) Biol Blood Marrow Transplant 2018 08;24(8):1610-1614 PMID: 29751116 SCOPUS ID: 2-s2.0-85048069667 05/12/2018       3 Citations
  • Outcomes of Medicare-age eligible NHL patients receiving RIC allogeneic transplantation: a CIBMTR analysis. (Shah NN, Ahn KW, Litovich C, Fenske TS, Ahmed S, Battiwalla M, Bejanyan N, Dahi PB, Bolaños-Meade J, Chen AI, Ciurea SO, Bachanova V, DeFilipp Z, Epperla N, Farhadfar N, Herrera AF, Haverkos BM, Holmberg L, Hossain NM, Kharfan-Dabaja MA, Kenkre VP, Lazarus HM, Murthy HS, Nishihori T, Rezvani AR, D'Souza A, Savani BN, Ulrickson ML, Waller EK, Sureda A, Smith SM, Hamadani M) Blood Adv 2018 04 24;2(8):933-940 PMID: 29685953 PMCID: PMC5916010 SCOPUS ID: 2-s2.0-85055419410 04/25/2018       15 Citations
  • Peripheral Blood Grafts for T Cell-Replete Haploidentical Transplantation Increase the Incidence and Severity of Cytokine Release Syndrome. (Raj RV, Hamadani M, Szabo A, Pasquini MC, Shah NN, Drobyski WR, Shaw BE, Saber W, Rizzo JD, Jerkins J, Fenske TS, D'Souza A, Dhakal B, Zhang C, Konings S, Hari PN, Chhabra S) Biol Blood Marrow Transplant 2018 08;24(8):1664-1670 PMID: 29680516 SCOPUS ID: 2-s2.0-85047194888 04/24/2018       17 Citations
  • Use of propylene glycol-free melphalan conditioning in light-chain amyloidosis patients undergoing autologous hematopoietic cell transplantation is well tolerated and effective. (Badar T, Hari P, Chhabra S, Dhakal B, Drobyski WR, Fenske TS, Hamadani M, Pasquini M, Saber W, Shah NN, Shaw BE, D'Souza A) Bone Marrow Transplant 2018 09;53(9):1210-1213 PMID: 29679076 SCOPUS ID: 2-s2.0-85045751124 04/22/2018       2 Citations
  • Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure. (Smith SM, Godfrey J, Ahn KW, DiGilio A, Ahmed S, Agrawal V, Bachanova V, Bacher U, Bashey A, Bolaños-Meade J, Cairo M, Chen A, Chhabra S, Copelan E, Dahi PB, Aljurf M, Farooq U, Ganguly S, Hertzberg M, Holmberg L, Inwards D, Kanate AS, Karmali R, Kenkre VP, Kharfan-Dabaja MA, Klein A, Lazarus HM, Mei M, Mussetti A, Nishihori T, Ramakrishnan Geethakumari P, Saad A, Savani BN, Schouten HC, Shah N, Urbano-Ispizua A, Vij R, Vose J, Sureda A, Hamadani M) Cancer 2018 06 15;124(12):2541-2551 PMID: 29645093 PMCID: PMC5990449 SCOPUS ID: 2-s2.0-85045242474 04/13/2018       16 Citations
  • What is the standard of care for primary mediastinal B cell lymphoma; R-CHOP or DA-EPOCH-R? - Response to Melani et al. (Shah NN, Fenske TS, Hamadani M, Svoboda J) Br J Haematol 2019 03;184(5):838-840 PMID: 29528099 SCOPUS ID: 2-s2.0-85043472454 03/13/2018    
  • Leukemic phase and CSF involvement of diffuse large B-cell lymphoma with a complex karyotype including a TP53 deletion. (Sinkoff J, Olteanu H, Peterson JF, Shah NN) Clin Case Rep 2018 01;6(1):235-237 PMID: 29375876 PMCID: PMC5771872 01/30/2018    
  • Graft-versus-host disease-associated hepatic portal venous gas. (Singavi AK, Shah NN) Br J Haematol 2018 04;181(1):9 PMID: 29363735 SCOPUS ID: 2-s2.0-85041005174 01/25/2018    
  • Choosing Wisely BMT: American Society for Blood and Marrow Transplantation and Canadian Blood and Marrow Transplant Group's List of 5 Tests and Treatments to Question in Blood and Marrow Transplantation. (Bhella S, Majhail NS, Betcher J, Costa LJ, Daly A, Dandoy CE, DeFilipp Z, Doan V, Gulbis A, Hicks L, Juckett M, Khera N, Krishnan A, Selby G, Shah NN, Stricherz M, Viswabandya A, Bredeson C, Seftel MD) Biol Blood Marrow Transplant 2018 05;24(5):909-913 PMID: 29360515 SCOPUS ID: 2-s2.0-85044666234 01/24/2018       13 Citations
  • Tocilizumab, tacrolimus and methotrexate for the prevention of acute graft-versus-host disease: low incidence of lower gastrointestinal tract disease. (Drobyski WR, Szabo A, Zhu F, Keever-Taylor C, Hebert KM, Dunn R, Yim S, Johnson B, D'Souza A, Eapen M, Fenske TS, Hari P, Hamadani M, Horowitz MM, Rizzo JD, Saber W, Shah N, Shaw B, Pasquini M) Haematologica 2018 04;103(4):717-727 PMID: 29351985 PMCID: PMC5865423 SCOPUS ID: 2-s2.0-85044420638 01/21/2018       13 Citations
  • Closed-system manufacturing of CD19 and dual-targeted CD20/19 chimeric antigen receptor T cells using the CliniMACS Prodigy device at an academic medical center. (Zhu F, Shah N, Xu H, Schneider D, Orentas R, Dropulic B, Hari P, Keever-Taylor CA) Cytotherapy 2018 03;20(3):394-406 PMID: 29287970 SCOPUS ID: 2-s2.0-85039050230 12/31/2017       20 Citations
  • R-CHOP versus dose-adjusted R-EPOCH in frontline management of primary mediastinal B-cell lymphoma: a multi-centre analysis. (Shah NN, Szabo A, Huntington SF, Epperla N, Reddy N, Ganguly S, Vose J, Obiozor C, Faruqi F, Kovach AE, Costa LJ, Xavier AC, Okal R, Kanate AS, Ghosh N, Kharfan-Dabaja MA, Strelec L, Hamadani M, Fenske TS, Calzada O, Cohen JB, Chavez J, Svoboda J) Br J Haematol 2018 02;180(4):534-544 PMID: 29265182 SCOPUS ID: 2-s2.0-85038422379 12/22/2017       24 Citations
  • Fludarabine and Busulfan versus Fludarabine, Cyclophosphamide, and Rituximab as Reduced-Intensity Conditioning for Allogeneic Transplantation in Follicular Lymphoma. (Epperla N, Ahn KW, Armand P, Jaglowski S, Ahmed S, Kenkre VP, Savani B, Jagasia M, Shah NN, Fenske TS, Sureda A, Smith SM, Hamadani M) Biol Blood Marrow Transplant 2018 01;24(1):78-85 PMID: 29032272 PMCID: PMC5743624 SCOPUS ID: 2-s2.0-85034849252 10/17/2017       2 Citations
  • Etanercept and Corticosteroid Therapy for the Treatment of Late-Onset Idiopathic Pneumonia Syndrome. (Thompson J, Yin Z, D'Souza A, Fenske T, Hamadani M, Hari P, Rizzo JD, Pasquini M, Saber W, Shah N, Shaw BE, Shahir K, Banerjee A, Drobyski WR) Biol Blood Marrow Transplant 2017 Nov;23(11):1955-1960 PMID: 28757436 SCOPUS ID: 2-s2.0-85028446880 08/02/2017       5 Citations
  • Alpha-1-antitrypsin for the treatment of steroid-refractory acute gastrointestinal graft-versus-host disease. (Jerkins JH, Hamadani M, Zook F, Epperla N, Shaw BE, Saber W, Rizzo JD, Pasquini M, Chhabra S, Drobyski WR, Hari PN, Shah NN) Am J Hematol 2017 Oct;92(10):E610-E611 PMID: 28699171 SCOPUS ID: 2-s2.0-85026445343 07/13/2017       3 Citations
  • Local Disease Control in Ocular Adnexal Lymphoproliferative Disorders: Comparative Outcomes of MALT Versus Non-MALT Histologies. (Dhakal B, Fenske TS, Ramalingam S, Shuff J, Epperla N, Hosking P, Rein L, Banerjee A, Hari P, D'Souza A, Shah N, Siker M, Griepentrog GJ, Harris GJ, Wells TS, Erickson BA, Hamadani M) Clin Lymphoma Myeloma Leuk 2017 05;17(5):305-311.e2 PMID: 28284742 SCOPUS ID: 2-s2.0-85015693044 03/13/2017       4 Citations
  • Split-dose R-CHOP: A new approach to administer cytotoxic chemo-immunotherapy to elderly patients with DLBCL (Shah NN, Mitra N, Brikman J, Nasta S, Landsburg D, Mato A, Vogl D, Frey N, Schuster SJ, Svoboda J) Journal of Community and Supportive Oncology November 2016;14(11):450-456 SCOPUS ID: 2-s2.0-85000762818 11/01/2016    
  • Extracavitary primary effusion lymphoma associated with hemophagocytic lymphohistiocytosis. (Epperla N, Harrington AM, Hemauer K, Shah NN) Am J Hematol 2016 Nov;91(11):1161-1164 PMID: 27414752 SCOPUS ID: 2-s2.0-84989227504 10/21/2016       2 Citations
  • Acute promyelocytic leukemia presenting as a paraspinal mass. (Shah NN, Stonecypher M, Gopal P, Luger S, Bagg A, Perl A) J Community Support Oncol 2016 Mar;14(3):126-9 PMID: 27058871 04/09/2016    
  • Improving the Safety of Oral Chemotherapy at an Academic Medical Center. (Shah NN, Casella E, Capozzi D, McGettigan S, Gangadhar TC, Schuchter L, Myers JS) J Oncol Pract 2016 Jan;12(1):e71-6 PMID: 26733627 PMCID: PMC4960462 SCOPUS ID: 2-s2.0-84958581892 01/07/2016       13 Citations
  • Implementation of an Advanced Practice Provider Service on an Allogeneic Stem Cell Transplant Unit: Impact on Patient Outcomes. (Shah NN, Kucharczuk CR, Mitra N, Hirsh R, Svoboda J, Porter D, Loren A, Frey N, Schapira MM) Biol Blood Marrow Transplant 2015 Sep;21(9):1692-8 PMID: 26028503 SCOPUS ID: 2-s2.0-84938993007 06/02/2015       1 Citation
  • The role of FDG-PET imaging as a prognostic marker of outcome in primary mediastinal B-cell lymphoma. (Nagle SJ, Chong EA, Chekol S, Shah NN, Nasta SD, Glatstein E, Plastaras JP, Torigian DA, Schuster SJ, Svoboda J) Cancer Med 2015 Jan;4(1):7-15 PMID: 25205600 PMCID: PMC4312112 SCOPUS ID: 2-s2.0-85005781388 09/11/2014       11 Citations
  • Extracavitary primary effusion lymphoma initially presenting with hemophagocytic lymphohistocytosis. (Shah NN, Harrison N, Stonecypher M, Frank D, Amorosa V, Svoboda J) Clin Lymphoma Myeloma Leuk 2014 Oct;14(5):e157-60 PMID: 25027567 SCOPUS ID: 2-s2.0-84908663975 07/17/2014       5 Citations
  • Plasmacytic post-transplant lymphoproliferative disorder: a case series of nine patients. (Karuturi M, Shah N, Frank D, Fasan O, Reshef R, Ahya VN, Bromberg M, Faust T, Goral S, Schuster SJ, Stadtmauer EA, Tsai DE) Transpl Int 2013 Jun;26(6):616-22 PMID: 23551167 SCOPUS ID: 2-s2.0-84878012301 04/05/2013       19 Citations
  • Last update: 08/31/2020
    jenkins-FCD Prod-480 9a4deaf152b0b06dd18151814fff2e18f6c05280